

**ATAGI COVID Working Group
Subgroup 3, Meeting No. 21
10 June 2021, 11:30 – 12:30pm**

In attendance:

Members	NCIRS Technical Staff	Department of Health reps
Nigel Crawford - lead	s 47F	s 22
Tony Korman		Darius Everett
John Kaldor		s 22
Paul Effler		Leanne Ringwood
Katie Attwell		s 22
Chris Blyth		
Debra Petrys		
Kristy Cooper		Secretariat
Margie Danchin	Invited Representatives	s 22
Cheryl Jones	s 47F	
Kristine Macartney		

1. Welcome and apologies / general committee business

Members:

- NOTED acknowledgement to country
- NOTED attendees and apologies (Catherine King, Christine Selvey, Alan Leeb)

s 47F

- Declared no conflicts of interest.

2. Outcomes from previous meeting

Members ENDORSED outcomes and actions from previous meeting with no amendments.

3. TTS information for primary care

Members NOTED and DISCUSSED:

- How ATAGI can provide guidance in identification, referral and management of suspected TTS cases after AstraZeneca COVID-19 vaccine in primary care (GP, Emergency)
- Importance of patient and healthcare provider awareness of TTS symptoms
- Emergency waiting times and how suspected TTS cases can be flagged and escalated quickly
- Cues to support nurses who are not immunisers (e.g. AstraZeneca vaccine as screening question)
- Jurisdictions are collecting TTS mortality and morbidity information
- Importance of including full TTS cases in risk-benefit document, as estimated rates/ratio may be difficult for the public to interpret
 - Risk-benefit document is currently being updated.

Action	Responsible officer/s	Progress
3.1 Draft 1-2 pager guidance on TTS management in primary care <ul style="list-style-type: none"> • Draft guidance for ACEM review • RACGP to disseminate to members 	NCIRS/SG3	To progress

4. TGA update

Nil.

**ATAGI COVID Working Group
Subgroup 3, Meeting No. 21
10 June 2021, 11:30 – 12:30pm**

s 22

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982 (CTH)
BY THE DEPARTMENT OF HEALTH

Meeting closed at 12:35pm.